Objective: To study the role of SV40 early region gene coding product large tumor antigen(Tag) expression and the interaction between Tag and tumor suppressors p53 and pRb in human brain tumorigenesis. Methods: Tag wa...Objective: To study the role of SV40 early region gene coding product large tumor antigen(Tag) expression and the interaction between Tag and tumor suppressors p53 and pRb in human brain tumorigenesis. Methods: Tag was investigated by immunoprecipitation followed by silver staining and Western blot in 65 cases of human brain tumors and 8 cases of normal brain tissues. Tag-p53 and Tag-pRb complexes were screened by immunoprecipitation and Western blot in 18 and 15 Tag positive tumor tissues respectively. Results: SV40 Tag was expressed generally in human brain tumors, its positive rate was 66. 2% (43 /65). However, Eight normal brain tissues were all negative for Tag, there was significant difference between them(P < 0. 05). Tag-p53 complex was detected in all of 18 Tag positive tumors as well as Tag-pRb complex in all of 15 Tag positive tumors. Conclnsion: SV40 Tag expression is associated with human brain tumorigenesis. The inactivation of p53 and pRh due to the formation of Tag-p53 and Tag-pRb complexes is possibly an important mechanism in the etiopathogenesis of human brain tumors.展开更多
Objective: To investigate the detecting method and diagnostic value of the tumor marker colorectal carcinoma associated large external antigen (LEA) for colorectal carcinoma. Methods: Monoclonal antibody ND-1, which c...Objective: To investigate the detecting method and diagnostic value of the tumor marker colorectal carcinoma associated large external antigen (LEA) for colorectal carcinoma. Methods: Monoclonal antibody ND-1, which can recognize LEA, was labeled with biotin aminocaproylhydrazide (BACH) and horseradish peroxidase (HRP) respectively. One step sandwich ELISA Kit for detecting LEA in serum was developed by the biotinylated antibody and enzyme conjugation. The validity and reliability of the kit were evaluated by sera selected from clinic. Results: the OD405 of healthy group was 0.056±0.038, and that of patients was 0.553±0.441. The difference between the two groups was significant (P<0.01). The cutoff value, which was 0.248, was determined by analysis of ROC. The diagnosis sensitivity, specificity and validity of the kit were 89.29%, 87.5%, 88.54% respectively. The ROC value was 0.95. The intra-CV was less than 5%, and the internal-CV was less than 10%. There was no significant difference between the results obtained by the kit and those obtained by pathological diagnosis (P<0.01). The expression of LEA was associated with the differentiated degree of colorectal carcinoma and had no relation to the Dukes’ phase of the disease. Conclusion: LEA is practically useful tumor marker for the diagnosis of colorectal carcinoma. The kit developed can be used for the qualitative diagnosis for the disease.展开更多
Anti-CD19 chimeric antigen receptor(CAR)-T cell therapy has achieved 40%–50%long-term complete response in relapsed or refractory diffuse large B-cell lymphoma(DLBCL)patients.However,the underlying mechanism of alter...Anti-CD19 chimeric antigen receptor(CAR)-T cell therapy has achieved 40%–50%long-term complete response in relapsed or refractory diffuse large B-cell lymphoma(DLBCL)patients.However,the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cell therapy failure needs further investigation.A multi-center phase I/II trial of anti-CD19 CD28z CAR-T(FKC876,ChiCTR1800019661)was conducted.Among 22 evaluable DLBCL patients,seven achieved complete remission,10 experienced partial remissions,while four had stable disease by day 29.Single-cell RNA sequencing results were obtained from core needle biopsy tumor samples collected from long-term complete remission and early-progressed patients,and compared at different stages of treatment.M2-subtype macrophages were significantly involved in both in vivo and in vitro anti-tumor functions of CAR-T cells,leading to CAR-T cell therapy failure and disease progression in DLBCL.Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy,during both cell expansion and disease progression,which could not be altered by infiltrating CAR-T cells.Aberrant metabolism profile of M2-subtype macrophages and those of dysfunctional T cells also contributed to the immunosuppressive tumor microenvironments.Thus,our findings provided a clinical rationale for targeting tumor microenvironments and reprogramming immune cell metabolism as effective therapeutic strategies to prevent lymphoma relapse in future designs of CAR-T cell therapy.展开更多
Objective: To investigate the expression of SV40 Tag and formation of Tag-p53 and Tag-Rb complexes in Chinese brain tumors. Methods: SV40 large tumor antigen (Tag) were investigated by immunoprecipitation, silver stai...Objective: To investigate the expression of SV40 Tag and formation of Tag-p53 and Tag-Rb complexes in Chinese brain tumors. Methods: SV40 large tumor antigen (Tag) were investigated by immunoprecipitation, silver staining and Western blot in 65 cases of Chinese brain tumors and 8 cases of normal brain tissues. Tag-p53 and Tag-Rb complexes were screened by the same way in 20 and 15 Tag positive tumor tissues respectively. Results: Tag was found in all of 8 ependymomas and 2 choroid plexus papillomas, 90% (9/10) of pituitary adenomas, 73% (11/15) of astrocytomas, 70% (7/10) of meningiomas, 50% (4/8) of glioblastoma multiform, 33% (2/6) of medulloblastomas, 5 oligodendrogliomas, 1 pineocytoma and 8 normal brain tissues were negative for Tag. Tag-p53 complex was detected in all of 20 Tag positive tumors as well as Tag-Rb complex in all of 15 Tag positive tumors. Conclusion: SV40 Tag is not only expressed in human brain tumors, but also it can form specific complexes with tumor suppressors p53 and Rb. SV40 is correlated to human brain tumorigenesis. The inactivation of p53 and Rb due to the formation of Tag-p53 and Tag-Rb complexes is possibly an important mechanism in the etiopathogenesis of human brain tumors.展开更多
基金National Natural Science Foundation of China!No.39470724
文摘Objective: To study the role of SV40 early region gene coding product large tumor antigen(Tag) expression and the interaction between Tag and tumor suppressors p53 and pRb in human brain tumorigenesis. Methods: Tag was investigated by immunoprecipitation followed by silver staining and Western blot in 65 cases of human brain tumors and 8 cases of normal brain tissues. Tag-p53 and Tag-pRb complexes were screened by immunoprecipitation and Western blot in 18 and 15 Tag positive tumor tissues respectively. Results: SV40 Tag was expressed generally in human brain tumors, its positive rate was 66. 2% (43 /65). However, Eight normal brain tissues were all negative for Tag, there was significant difference between them(P < 0. 05). Tag-p53 complex was detected in all of 18 Tag positive tumors as well as Tag-pRb complex in all of 15 Tag positive tumors. Conclnsion: SV40 Tag expression is associated with human brain tumorigenesis. The inactivation of p53 and pRh due to the formation of Tag-p53 and Tag-pRb complexes is possibly an important mechanism in the etiopathogenesis of human brain tumors.
基金China Innovative Foundation for Medium and Mini Sized Technological Enterprise.
文摘Objective: To investigate the detecting method and diagnostic value of the tumor marker colorectal carcinoma associated large external antigen (LEA) for colorectal carcinoma. Methods: Monoclonal antibody ND-1, which can recognize LEA, was labeled with biotin aminocaproylhydrazide (BACH) and horseradish peroxidase (HRP) respectively. One step sandwich ELISA Kit for detecting LEA in serum was developed by the biotinylated antibody and enzyme conjugation. The validity and reliability of the kit were evaluated by sera selected from clinic. Results: the OD405 of healthy group was 0.056±0.038, and that of patients was 0.553±0.441. The difference between the two groups was significant (P<0.01). The cutoff value, which was 0.248, was determined by analysis of ROC. The diagnosis sensitivity, specificity and validity of the kit were 89.29%, 87.5%, 88.54% respectively. The ROC value was 0.95. The intra-CV was less than 5%, and the internal-CV was less than 10%. There was no significant difference between the results obtained by the kit and those obtained by pathological diagnosis (P<0.01). The expression of LEA was associated with the differentiated degree of colorectal carcinoma and had no relation to the Dukes’ phase of the disease. Conclusion: LEA is practically useful tumor marker for the diagnosis of colorectal carcinoma. The kit developed can be used for the qualitative diagnosis for the disease.
基金the National Natural Science Foundation of China(Nos.81830007,82130004,81600155,and 81670716)Clinical Research Plan of SHDC(No.2020CR1032B),Shanghai Rising-Star Program(No.19QA145600)+5 种基金Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai(No.2017YQ075)Talent(Class A)of Guangci Excellence Youth Plan(No.GCQN-2019-A16)Clinical Research Plan of Shanghai Hospital Development Center(No.SHDC2020CR1032B)Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support(Nos.20152206 and 20152208)China CAR-T Clinical Research Fund Project(No.CARTFR-05)Samuel Waxman Cancer Research Foundation.
文摘Anti-CD19 chimeric antigen receptor(CAR)-T cell therapy has achieved 40%–50%long-term complete response in relapsed or refractory diffuse large B-cell lymphoma(DLBCL)patients.However,the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cell therapy failure needs further investigation.A multi-center phase I/II trial of anti-CD19 CD28z CAR-T(FKC876,ChiCTR1800019661)was conducted.Among 22 evaluable DLBCL patients,seven achieved complete remission,10 experienced partial remissions,while four had stable disease by day 29.Single-cell RNA sequencing results were obtained from core needle biopsy tumor samples collected from long-term complete remission and early-progressed patients,and compared at different stages of treatment.M2-subtype macrophages were significantly involved in both in vivo and in vitro anti-tumor functions of CAR-T cells,leading to CAR-T cell therapy failure and disease progression in DLBCL.Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy,during both cell expansion and disease progression,which could not be altered by infiltrating CAR-T cells.Aberrant metabolism profile of M2-subtype macrophages and those of dysfunctional T cells also contributed to the immunosuppressive tumor microenvironments.Thus,our findings provided a clinical rationale for targeting tumor microenvironments and reprogramming immune cell metabolism as effective therapeutic strategies to prevent lymphoma relapse in future designs of CAR-T cell therapy.
基金This work was supported by China Postdoctoral Science Foundation (No. 1998-23).
文摘Objective: To investigate the expression of SV40 Tag and formation of Tag-p53 and Tag-Rb complexes in Chinese brain tumors. Methods: SV40 large tumor antigen (Tag) were investigated by immunoprecipitation, silver staining and Western blot in 65 cases of Chinese brain tumors and 8 cases of normal brain tissues. Tag-p53 and Tag-Rb complexes were screened by the same way in 20 and 15 Tag positive tumor tissues respectively. Results: Tag was found in all of 8 ependymomas and 2 choroid plexus papillomas, 90% (9/10) of pituitary adenomas, 73% (11/15) of astrocytomas, 70% (7/10) of meningiomas, 50% (4/8) of glioblastoma multiform, 33% (2/6) of medulloblastomas, 5 oligodendrogliomas, 1 pineocytoma and 8 normal brain tissues were negative for Tag. Tag-p53 complex was detected in all of 20 Tag positive tumors as well as Tag-Rb complex in all of 15 Tag positive tumors. Conclusion: SV40 Tag is not only expressed in human brain tumors, but also it can form specific complexes with tumor suppressors p53 and Rb. SV40 is correlated to human brain tumorigenesis. The inactivation of p53 and Rb due to the formation of Tag-p53 and Tag-Rb complexes is possibly an important mechanism in the etiopathogenesis of human brain tumors.